https://www.selleckchem.com/products/cpi-203.html
Breast MRI background parenchymal enhancement (BPE) can potentially serve as a prognostic marker, by possible correlation with molecular subtype. Oncotype Dx, a gene assay, is a prognostic and predictive surrogate for tumor aggressiveness and treatment response. The purpose of this study was to investigate the association between contralateral non-tumor breast magnetic resonance imaging (MRI) background parenchymal enhancement and tumor oncotype score. In this retrospective study, patients with ER+ and HER2- early stage invasive ductal
Aimer
Commentaire
Partagez
